ESMO TAT 2021 | Cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer

Cedric Pobel, MD, Gustave Roussy Institute, Villejuif, France, discusses the efficacy of cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer. In a cohort of 22 patients receiving 3 lines of cabazitaxel, most patients had a long progression-free survival (PFS), and a prostate-specific antigen (PSA) response of 86.4% and 63.6% for first-use and second-use patients, respectively. Along with an absence of cumulative toxicity, this study demonstrates the feasibility of cabazitaxel multiple rechallenges in patients, especially ones who have exhausted multiple treatment options. This interview took place during the ESMO TAT 2021 conference.